Strong 2024 for Astellas as Vyloy momentum builds

Japanese pharma major Astellas Pharma (TSE: 4503) delivered a strong performance in fiscal 2024, with revenue rising 19% to 1.91 trillion yen ($12.6 billion) and core profit climbing 33% to 295.7 billion yen.

Gains were fueled by expanding sales of Xtandi (enzalutamide), Padcev (enfortumab vedotin), Izervay (avacincaptad pegol), and new launches including Vyloy (zolbetuximab). Revenue in the USA grew more than 30%.

Vyloy, a therapy for gastric and gastroesophageal junction cancers, was highlighted as a standout performer in the latest fiscal year. Astellas noted that faster adoption of Claudin 18.2 biomarker testing had contributed to sales exceeding expectations.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK